|
 |
RebifThis page contains recent news articles, when available, and an overview of Rebif but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The company has strong market positions in neurodegenerative diseases, with Rebif® (interferon beta-1a), as well as in endocrinology, with Saizen® ... PR Newswire (press release) Merck Serono Initiates KAMPER, the First Pan-European Registry for Patients ... - Dec 10, 2009 Merck Serono has leading brands serving patients with cancer (Erbitux(R), cetuximab), multiple sclerosis (Rebif(R), interferon beta-1a), ... FOXBusiness Merck KGaA hält nach jüngster Pechsträhne an Pharmastrategie fest - Dec 14, 2009 Das heisst, es kann als Tablette eingenommen werden und muss nicht wie die gängigen Mittel wie etwa Rebif von Merck und das Bayer-Medikament Betaferon ... Handelszeitung Online Sergantieji IS negauna pažangių vaistų – naÅ¡ta valstybei didÄ—ja - Dec 14, 2009 Paskirtas gydymas – interferonu beta-1a (Rebif), taÄ?iau paÅ«mÄ—jimai kartojasi kas 3–6 mÄ—n. NorÄ—damas parodyti, kÄ… gali sergantysis IS, jis konferencijos ... medicine.lt Merck Serono kundigt Grundlagenforschung und klinischer Forschung bei ... - Dec 16, 2009 Merck Serono verfugt uber fuhrende Marken, die Patienten bei Krebs (Erbitux(R), Cetuximab), Multipler Sklerose (Rebif(R), Interferon beta-1a), ... news aktuell Schweiz (Pressemitteilung) Merck Serono annonce une collaboration en recherche fondamentale et en ... - Dec 16, 2009 ...de la sclérose en plaques (Rebif(R), interféron-bêta 1a), de la médecine de la reproduction (Gonal-f(R), follitropine-alfa), des troubles endocriniens ... Capital.fr UPDATE 1-Merck KGaA sees liquid crystals rebounding - Oct 26, 2009 He said that the euro's recent strength seems to have weighed on the business, which includes cancer drug Erbitux and multiple sclerosis treatment Rebif. ... Reuters Research offers new hope to MS sufferers - Nov 10, 2009 ..."All five"--Avonex, Betaseron, Copaxone, Rebif and Tysabri-- "are drug therapies that attenuate the disease by helping control the intensity and frequency ... Calgary Herald Pfizer (PFE) Earns OK - Oct 20, 2009 Operational growth of 6%, largely driven by the solid performance of Rebif and Revatio. Oncology revenue was $371 million, a decrease of 5% compared with ... 24/7 Wall St. (blog) New drug therapies and promising research offer hope to MS sufferers - Nov 13, 2009 ..."All five" — Avonex, Betaseron, Copaxone, Rebif and Tysabri — "are drug therapies that attenuate the disease by helping control the intensity and frequency ... Vancouver Sun Merck starts breast-cancer trial - Nov 5, 2009 Merck needs new drugs to help it weather competition to its best-seller, Rebif, when the multiple sclerosis treatment loses patent protection in 2012. Hospital Healthcare Europe Breast Cancer Vaccine Tests German Merck's $1 Billion Strategy - Nov 3, 2009 Merck needs new drugs to help it weather competition to its best-seller, Rebif, when the multiple sclerosis treatment loses patent protection in 2012, ... Bloomberg All Tysabri, All the Time - Oct 20, 2009 ...sclerosis drugs such as Teva Pharmaceutical's (Nasdaq: TEVA) Copaxone, Novartis' (NYSE: NVS) Extavia, and Rebif from Pfizer (NYSE: PFE) and EMD Serono. ... Motley Fool For Tysabri, 23 Is 10 Too Many - Oct 26, 2009 The drug works better than other multiple sclerosis drugs such as Teva Pharmaceutical's (Nasdaq: TEVA) Copaxone, Novartis' (NYSE: NVS) Extavia, and Rebif ... Motley Fool Pfizer Reports Third-Quarter 2009 Results - Oct 20, 2009 Operational growth of 6%, largely driven by the solid performance of Rebif and Revatio, was partially offset by the unfavorable impact of foreign exchange. ... Reuters Video: EMD Serono Holds Topping Off Ceremony to Mark Milestone in the ... - Oct 19, 2009 The company has strong market positions in neurodegenerative diseases, with Rebif(®) (interferon beta-1a), as well as in endocrinology, with Saizen(®) ... Reuters KORREKTUR: Merck KGaA bestätigt und präzisiert Jahresprognose (zwei) - Oct 26, 2009 ...(In der um 7.29 Uhr gesendeten Meldung muss es im letzten Satz richtig heißen: Mit "Erbitux" NICHT "Rebif" erlöste Merck 177 Mio EUR, 33% mehr als in der ... Märkische Allgemeine Rebif® reduz em 69% lesões da esclerose múltipla - Oct 29, 2009 Os resultados mais recentes do estudo IMPROVE revelam que o tratamento com Rebif® (em regime de 44 microgramas três vezes durante 16 semanas) contribui para ... RCM Pharma Caen utilidades de Merck - Oct 26, 2009 ...en el tercer trimestre un 5,8 por ciento hasta 1.313 millones de euros (1.969 millones de dólares) gracias a medicamentos como Rebif, Erbitux y Gonal-f. ... El Financiero (México) Merck KGaA erfüllt mit 3Q Erwartungen - LC-Erholung hält an - Oct 26, 2009 Die weltweiten Umsatzerlöse von "Rebif" kletterten im Quartal um 13% auf 381 Mio EUR. Mit "Erbitux" erlöste Merck im Quartal 177 Mio EUR, 33% mehr als im ... Märkische Allgemeine Una 'ayuda' electrónica para la esclerosis - Oct 23, 2009 ...el RebiSmart, comercializado por Merck_Serono y que facilita la administración del fármaco, el interferón beta-1a (Rebif), y registra la fecha y la hora ... elmundo.es Les pénuries de médicaments vitaux causent de nombreux décès - Oct 25, 2009 Selon Mme Bahamid, des pénuries touchent des médicaments indispensables, comme le Rebif et Imurel. Mme Bahamid cite l'exemple de Imurel, est un médicament ... La Tribune d'Algérie Merck Revenues Increase by 2.7% to € 1.9 Billion - Oct 26, 2009 Merck KGaA announced today that Group total revenues rose 2.7% in the third quarter to € 1944 million from € 1893 million in the year-ago quarter as the ... apothekersnieuws.nl Les signes de la reprise é… - Nov 12, 2009 La plupart des revenus proviennent du médicament contre la sclérose multiple Rebif, qui a été initialement développé à l'Institut Weizmann. ... IsraelValley ë?…ì?¼ ë©œí?¬, 암치료 ë°±ì‹ ìŠ¤í‹°ë¬´ë°•ìŠ¤ 개발ì—? í?° 기대 - Nov 8, 2009 ...ë©œí?¬ëŠ” 다발성 경화ì¦? ì¹˜ë£Œì œ ë ˆë¹„í”„(Rebif)ì?˜ 특허가 2012ë…„ 만료ë?˜ë¯€ë¡œ ì‹ ì•½ 출시가 ì ˆëŒ€ë¡œ 필요한 ì‹œì ?ì?´ë?¼ê³ 분ì„?í•˜ê³ ìžˆë‹¤. 룬드퀴스트씨는 스티무박스가 â€œê³ ... 메디포뉴스 Vacuna contra cáncer de mama - Nov 5, 2009 La empresa farmacéutica necesita nuevas medicinas para hacer frente a la competencia a su medicamento Rebif cuando en 2012 venza la patente del exitoso ... Diario La República - COLOMBIA Biogen Idec erzielt höheren Gewinn - Nachfrage nach Multiple-Sklerose-Mittel - Oct 20, 2009 Avonex, ein Konkurrenzprodukt zu Betaferon von Bayer und Rebif vom Darmstädter Pharma- und Chemiekonzern Merck , verbuchte ein marginales Umsatzplus von 1 ... Handelszeitung Online AUSBLICK/Merck KGaA zeigt solides Pharmageschäft - LC-Erholung hält an - Oct 22, 2009 Analysten erwarten, dass die Gesamterlöse in der größten Sparte Merck Serono, getrieben von dem Multiple Sklerose Mittel "Rebif" und dem Krebsmedikament ... FOCUS Online Q3 2009: Gesamterlöse von Merck steigen um 2,7% auf 1,9 Mrd € - Oct 29, 2009 Die weltweiten Umsatzerlöse von Rebif zur Behandlung von schubförmiger Multipler Sklerose (MS) wuchsen im 3. Quartal um 13% auf 381 Mio €. ... News-Ticker.org (Pressemitteilung) Serono still confident MS drug Rebif will achieve market leadership - Mar 9, 2006 ZURICH (AFX) - Serono SA said it remains confident of achieving market leadership with its key multiple sclerosis treatment Rebif despite yesterday's vote ... Forbes German Merck says FDA seeks more data on Rebif - Feb 6, 2007 FRANKFURT, Feb 6 (Reuters) - German Merck KGaA (MRCG.DE) said on Tuesday a US regulator has asked for more data on a new formulation of its multiple ... Reuters Germany's Merck says EU approves new Rebif version - Aug 30, 2007 FRANKFURT, Aug 30 (Reuters) - German drug maker Merck KGaA's (MRCG.DE) Merck Serono unit won European Commission approval to market a new formulation of its ... Reuters Serono files new Rebif formulation for US, European approval - Apr 4, 2006 ZURICH (AFX) - Serono SA said it has filed a supplemental Biologics Licence Application to the US FDA and for a variation to the current marketing ... Forbes Serono launches Rebif.net website for MS patients, physicians - Jun 22, 2005 GENEVA (AFX) - Swiss biotech company Serono SA announced the launch of Rebif.net, a new website for its key multiple sclerosis (MS) treatment Rebif, ... Forbes … KGaA receives EMEA recommendation of new Rebif formula to treat MS... - Jun 28, 2007 FRANKFURT (Thomson Financial) - Merck (nyse: MRK - news - people ) KGaA said the Committee for Medicinal Products for Human Use (CHMP) of the European ... Forbes Serono Q2 net profit rises 8 pct on Rebif boost - Jul 26, 2006 GENEVA Switzerland - Swiss pharmaceutical company Serono SA said second-quarter net profit rose 8 pct to 189.2 mln usd, helped by brisk sales in the US of ... Forbes Merck KGaA Has First-Quarter Profit on Erbitux, Rebif - Apr 23, 2008 By Eva von Schaper. April 23 (Bloomberg) -- Merck KGaA, the German maker of the Erbitux cancer medicine, reported first-quarter profit that beat analyst ... Bloomberg Rebif study, liquid crystals cloud German Merck - Oct 10, 2007 By Mantik Kusjanto. FRANKFURT, Oct 10 (Reuters) - Shares in German chemicals and drugs group Merck KGaA (MRCG.DE) fell as much as 2.7 percent on Wednesday ... Reuters Serono launches Rebif Phase III trials in patients at risk of... - Dec 12, 2006 ZURICH (AFX) - Serono SA said it will launch a new Phase III clinical trial to evaluate the effect of two dosage regimens of its new formulation of ... Forbes Serono results rise on Rebif sales - Feb 2, 2005 Leading biotechnology company Serono, which has US headquarters in Rockland, said sales and profit rose in the fourth quarter and for the full fiscal year, ... Bizjournals.com German Merck Profit Soars on Serono Deal - Feb 18, 2008 The increase was credited to stronger sales of Rebif and Erbitux. Globally, sales of Rebif _ part of the drug development pipeline acquired in the Serono ... FOXNews Genzyme halts drug test after death. - Sep 17, 2005 The test was designed to measure the effectiveness of Campath in comparison with Rebif, a drug now on the market to treat MS symptoms, which can include ... Free with registration - Boston Globe - AccessMyLibrary.com Genzyme's Campath May Slow MS - Oct 22, 2008 Campath also lowered the risk of sustained disability by 71% over Rebif, which is co-marketed by EMD Serono and Pfizer (PFE). ... BusinessWeek MS drug called effective, with checks for side effect - Oct 15, 2007 Results from a Phase II trial of 334 patients with multiple sclerosis showed the drug significantly reduced the risk of relapse compared to Rebif, ... Boston Globe Sale of Serono to Merck nets family £4.6bn - Sep 22, 2006 For example, Serono is in partnership with Pfizer to market Rebif. Michael Roemer, Merck chief executive, said: “This acquisition transforms Merck's ... Times Online Show Therapeutic Effect Of New Formulation Of Rebif(R) At 16 Weeks In... - Sep 24, 2008 Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd ... Medical News Today - Medical News Today (press release) Swiss Biotech Company May Seek a Buyer - Nov 9, 2005 Serono, which is based in Geneva, is best known for its multiple sclerosis product Rebif and is also a leader in infertility treatments. ... New York Times MS Guessing Game Heats Up - Mar 9, 2006 Serono could be vulnerable to a Tysabri comeback because Rebif accounted for ... If approved, Mylinax "could replace a significant portion of the Rebif ... TheStreet.com - TheStreet.com (subscription) Merck KGaA receives EMEA recommendation of Rebif to treat multiple … - Jun 28, 2007 FRANKFURT (Thomson Financial) - Merck KGaA said the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) ... Forbes Cancer 'Vaccine' Is Set Back as Treatment Fails in Trial - Apr 7, 2005 It was counting on Canvaxin and the psoriasis drug to help it diversify beyond the drugs on which it now depends, mainly Rebif for multiple sclerosis and ... New York Times Merck KGaA Net Falls Short on Crystals; Shares Drop - Jul 23, 2008 Erbitux sales rose 24 percent to 145 million euros, while Rebif revenue increased 2.8 percent to 320 million euros, boosting the pharma unit's overall ... Bloomberg Campath showing potential to treat multiple sclerosis - Sep 14, 2006 The study compares Campath with Rebif, a drug produced by Serono International SA, in the treatment of 334 multiple sclerosis patients over a three-year ... Bizjournals.com Serono relies on Rebif to boost 3Q - Oct 25, 2005 By Wai Lang Chu, 25-Oct-2005. Serono has announced a mixed third quarter 2005 with product sales and total revenues weaker than predicted. ... DrugResearcher.com Bayer, Genzyme start Alemtuzumab late trial for MS - Sep 26, 2007 DE) Rebif in patients with relapsing-remitting multiple-sclerosis (MS). MS is a chronic disease of the central nervous system in which the immune system can ... Reuters UK Merck KGaA starts new Phase III trial on MS pill - Sep 18, 2008 Merck is an established leader in MS treatment through its existing Rebif medicine, which was acquired when the German drugmaker bought Swiss biotech firm ... Reuters Serono Sets Aside Big Sum as US Inquiries Continue - Apr 23, 2005 Sales of its best-known product, the multiple sclerosis treatment Rebif, rose 13 percent, to $293 million. Large settlements in drug inquiries include TAP ... New York Times I will keep Serono on course, says sailor chief - Apr 21, 2006 Total sales of Rebif rose by 17 per cent to $327 million, although analysts had hoped to see the drug bring in $335 million, at least, during the quarter. ... Times Online Merck KGaA Net Falls on Serono Writedowns; Sales Gain (Correct) - Jul 26, 2007 There is still high dependence on the old Serono products like Rebif. ... Rebif sales rose 8.2 percent to 312 million euros for the quarter, while revenue ... Bloomberg Merck KGaA says Erbitux drug approved to treat colorectal cancer in … - Jul 16, 2008 It is Merck (nyse: MRK - news - people )'s most promising treatment and currently its second-best selling drug after Rebif, for multiple sclerosis. ... Forbes Drugmaker Serono Might Be For Sale - Nov 8, 2005 Geneva-based Serono's multiple sclerosis drug Rebif generated $316 million in revenue in the third quarter, and the company predicted that the medication ... Washington Post Serono shares slide on report it has no suitor - Jan 25, 2006 Rebif, whose sales rose 20 percent to $316 million in the third quarter, is targeted to be the worldwide ... Pfizer helps market Rebif in the United States. Boston Globe Merck Serono Has Initiated the ONWARD Study to Evaluate Oral … - Jan 24, 2007 The new formulation of Rebif(R) is under regulatory review by the European ... Rebif(R), which was approved in Europe in 1998 and in the US in 2002, ... RedOrbit Merck KGaA starts Phase III study of Erbitux on gastric cancer UPDATE - Jul 9, 2008 ...and for head and neck cancer, is Merck's most promising treatment and currently its second-best selling drug after Rebif, for multiple sclerosis. ... Forbes Despite Benefits, Genzyme Suspends Campath MS Trial - Sep 19, 2005 Non-serious adverse events included infusion reaction in the Campath patients, and flu-like symptoms in patients using Rebif. According to analyst Jennifer ... BioWorld Online - BioWorld Online EU recommends Rebif new formulation for MS patients - Jul 2, 2007 Merck KGaA announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion ... pharmabiz.com … Study Show Therapeutic Effect Of New Formulation Of Rebif(R) At 16... - Sep 23, 2008 ..."Patients who received Rebif(R) experienced far fewer new active brain MRI ... Patients who were initially assigned to the new formulation of Rebif(R) group ... Medical News Today - Medical News Today (press release) New Formulation Rebif for Relapsing Multiple Sclerosis Lowers … - Sep 30, 2006 By Bruce Sylvester. MADRID, SPAIN -- September 30, 2006 -- At 48 weeks into a 96 week phase 3b trial, a new formulation of Rebif (interferon beta-1a), ... DG News Double Dose of Disappointment for Serono - Apr 6, 2005 Serono is best known for Rebif, a multiple sclerosis treatment, which accounted for $1.1 billion of $2.5 billion in corporate revenue last year. ... TheStreet.com - TheStreet.com (subscription) Takeover costs dent Merck profit - Oct 24, 2007 Among Merck's products are cancer drug Erbitux and Rebif, inherited from Serono, to treat multiple sclerosis. Merck also sells liquid crystal compounds, ... BBC News GSK in line to snap up Serono for $12bn after auction collapse - Jan 29, 2006 A valuation of $15bn was put on the company, which makes a multiple sclerosis drug, Rebif, and infertility treatments. An auction attracted interest from ... Independent Merck 3Q net profit 200.1 million euros - Oct 27, 2008 Merck said its Rebif drug for treating multiple sclerosis was a big contributor, with sales increasing 10 percent to 338 million euros ($422.5 million). ... eTaiwan News Rivals Benefit From Biogen Drug Recall - Mar 1, 2005 Anticipating "a more benign competitive environment" in all markets, White predicted that Serono's sales of Rebif, which were $1.09 billion last year, ... TheStreet.com - TheStreet.com (subscription) German drug maker Merck posts 1st-quarter loss on acquisition of... - Apr 25, 2007 The company's operating profit rose to 321 million euros ($435.98 million) from 288 million euros a year earlier, lifted by demand for Erbitux and Rebif, ... San Diego Union - Tribune - San Diego Union Tribune Serono reverses sale plan and seeks buys - Apr 1, 2006 However, the company's attractiveness has been in doubt, with its top-selling multiple sclerosis drug, Rebif, facing the prospect of growing competition, ... Telegraph.co.uk Merck Says Profit at Serono Unit Rose on Rebif Drug - Mar 1, 2007 By Stefanie Haxel and Angela Cullen. March 1 (Bloomberg) -- Merck KGaA said fourth-quarter profit rose at Serono SA, the Swiss biotechnology company it ... Bloomberg Swiss shares higher in thin morning trade tracking Wall Street - Mar 13, 2006 ...down 21.50 sfr or 2.3 pct at 898, on continuing worries about a relaunch of Tysabri in the US, a rival of its key MS-treatment Rebif. ... Forbes … to Influenza Vaccine is Maintained in MS Patients Treated With... - Nov 9, 2005 One group of MS patients (n=86) received Rebif(R) (interferon beta-1a) 44 mcg subcutaneously three times weekly for at least six months before ... Free with registration - PR Newswire - AccessMyLibrary.com Is rebif a good medication for MS? Can anyone tell me about it? - Jun 1, 2008 I just found out I have MS and I am thinking about taking this medication. I take Rebif. From what I understand, all of the ABCR's have roughly the same ... HealthCentral.com German shares slightly down, with investors cautious ahead of... - Oct 15, 2007 ...relapses and was better at slowing the progress of disabilities than Merck (nyse: MRK - news - people ) KGaA's Rebif in a three-year phase II study. ... Forbes … : Serono Completes Patient Enrollment in Rebif(R) Versus Copaxone(R)... - Jan 5, 2005 Serono Completes Patient Enrollment in Rebif(R) Versus Copaxone(R) Comparative Clinical Trial. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Avonex, Betaseron and Rebif for Multiple Sclerosis - WebMD - Nov 2, 2006 Copaxone is an artificially made protein that resembles a protein that is part of the myelin that surrounds nerves. It is not known exactly how the drug ... WebMD … Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in... - Sep 17, 2008 Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis. from PR Newswire Europe. Pay-Per-View - PR Newswire Europe - HighBeam Research … Commission Approves Revision of Therapeutic Indication for Rebif(R)... - Jul 10, 2006 Throughout the European Union, Rebif(R) can now be prescribed after the ... The 'therapeutic indication' section of the SmPC of Rebif(R) now takes into ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: Serono Launches Rebif.net Website. - PR Newswire … - Jun 22, 2005 Serono Launches Rebif.net Website. from PR Newswire Europe. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire Europe - HighBeam Research MS Patients Have Significant And Sustained Reduction In Disability... - Oct 27, 2008 Importantly, the mean disability of patients on alemtuzumab improved from baseline, whereas the mean disability of those on Rebif worsened. ... Lifescience-online Multiple Sclerosis - New Rebif(R) Formulation Submitted In USA And … - Apr 10, 2006 Serono (virt-x:SEO and NYSE: SRA) announced today the submission of a supplemental Biologics Licence Application (sBLA) to the US Food and Drug ... Medical News Today - Medical News Today (press release) Press Release: Merck Serono's Rebif(R) Celebrates 10th Anniversary. -... - Jun 10, 2008 Merck Serono's Rebif(R) Celebrates 10th Anniversary. from PR Newswire Europe. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: Serono Submits New Formulation of Rebif(R) for... - Apr 4, 2006 Serono Submits New Formulation of Rebif(R) for Approval in the United States and in Europe. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Serono Completes Patient Enrollment in Rebif(R) Versus Copaxone(R) … - Jan 5, 2005 Serono (virt-x: SEO and NYSE: SRA) announced today that patient enrollment has been completed in a multi-national Rebif(R) (interferon beta-1a) versus ... $4.95 - PR Newswire - ECNext Merck KGaA Fourth-Quarter Profit Rose 18 Percent - Jan 18, 2007 Merck is buying Serono to become Europe's largest biotechnology company and add Rebif, the best-selling multiple sclerosis treatment outside the US The ... Bloomberg … Site Pain and Injection Site Reactions Than Rebif in Patients With... - Oct 4, 2006 Investigators analysed evaluable data on 303 patients on Betaferon and 142 on Rebif. Baseline characteristics of both groups of subjects were comparable. ... DG News … : New Formulation of Multiple Sclerosis Treatment Rebif(R) Approved... - Aug 30, 2007 New Formulation of Multiple Sclerosis Treatment Rebif(R) Approved in European Union. from PR Newswire Europe. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire Europe - HighBeam Research AAN: High-Dose Rebif Given Edge Over Avonex for Early MS - Apr 15, 2005 By Ed Susman,. MIAMI BEACH, April 15-There's a new skirmish in the on-going battle between the two formulations of interferon beta 1A for ... MedPage Today … Averts Some Side Effects of Switch From Avonex to Rebif in MS... - Oct 6, 2005 They randomised 35 subjects to receive Rebif 44 mcg 3 times weekly and 36 subjects to be titrated onto Rebif with 20% dosing the first week, 50% dosing the ... DG News Serono completes enrollment in Rebif vs Copaxone trial.(Brief Article) - Jan 3, 2005 Swiss biotechnology major Serono says that patient enrollment has been completed in a multinational Rebif (interferon beta-1a) versus Copaxone (glatiramer ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Therapy For Multiple Sclerosis - Serono And Syntonix Sign Worldwide … - Apr 4, 2005 Rebif® is the leading treatment for MS outside the US and the fastest growing ... Rebif®, which was approved in Europe in 1998 and in the US in 2002, ... i-newswire.com Hope for young MS victims - Jan 20, 2006 But since the Fredonia Central High School sophomore began injecting herself with Rebif, one of a group of drugs called beta-interferons, her symptoms have ... $2.95 - Buffalo News - NewsBank DJ MARKET TALK: Serono's New Rebif Seen Neutral For Forecasts - Sep 28, 2006 1351 GMT [Dow Jones] Serono's (SRA) new data on Rebif, suggesting that a new formulation of Rebif offers substantial improvements in tolerability, ... newratings.com Serono posts better-than-forecast Q3 results, driven by MS drug Rebif... - Oct 19, 2006 Rebif continued to be the group's biggest sales driver with sales reaching 374.8 mln usd, up 18.7 pct, or 15.4 pct in local currencies from the year-earlier ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com Merck Serono completes patient enrollment in REFLEX trial. - Sep 17, 2008 At this point, patients are offered open-label treatment with Rebif 44 ... Rebif is currently approved for the treatment of relapsing forms of MS. ... $9.94 - M2 Europharma - Alacra Store … the launch of a new website for its multiple sclerosis therapy... - Jun 23, 2005 This website offers an information to patients treated with Rebif, caregivers, nurses and physicians, as well as other people who might have an interest in ... OnMedica … Phase III Trial Show That New Formulation of Rebif(r) Offers... - Sep 28, 2006 One-year Data From Phase III Trial Show That New Formulation of Rebif(r) Offers Substantial Improvement in Tolerability and Immunogenicity Profiles. from PR ... Pay-Per-View - PR Newswire - HighBeam Research ALSO NOTED: Serono files sBLA for Rebif; Germany's Ingenium raises € … - Apr 3, 2006 ...> Switzerland's Serono has filed a supplemental BLA for a new formulation of its MS drug Rebif. According to Phase III data, the new formulation is more ... FierceBiotech … Mofetil (CellCept) and Interferon Beta (Rebif/Betaferon) Safe and ... - Oct 6, 2005 THESSALONIKI, GREECE -- October 6, 2005 -- Combination treatment with mycophenolate mofetil (MMF, CellCept) and interferon beta (INF-b, Rebif, or Betaferon) ... DG News Serono starts Rebif phase III trial - Dec 21, 2006 Serono has announced the initiation of a phase III clinical trial to evaluate the effect of two dosage regimens of the new formulation of Rebif (interferon ... pharmabiz.com … Vaccine is Maintained in MS Patients Treated With Rebif(R). - PR Ne - Nov 9, 2005 ..."These results demonstrate that treatment with Rebif(R) does not alter the ... Rebif(R) is the only approved MS therapy proven in a four-year clinical study ... Pay-Per-View - PR Newswire - HighBeam Research … of the Reflex Trial to Evaluate New Formulation of Rebif(R) in... - Dec 12, 2006 The trial, called the REFLEX study (REbif FLEXible dosing in early MS), ... Study participants will receive either the new formulation of Rebif(R) 44 mcg ... Pay-Per-View - PR Newswire - HighBeam Research SERONO PRESENTS DATA ON NEW REBIF FORMULATION - Oct 2, 2006 Serono has announced that data from an ongoing two-year Phase IIIb trial show that the new formulation of Rebif (interferon beta-1a) 44 micrograms ... Pay-Per-View - FDAnews Drug Pipeline Alert - Factiva, from Dow Jones Q3 2005 Serono SA Earnings Conference Call - Part 1. - Oct 2, 2005 Starting with Rebif. Our worldwide sales of Rebif continue to be strong, growing 19.8% to ... Outside the United States, Rebif sales grew by 14.5% to $213m. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com EU recommends new multiple sclerosis drug - Jul 3, 2007 The new formulation of Rebif was developed by the Merck Serono division to ... "While Rebif is well established in the treatment of multiple sclerosis, ... MaltaMedia … Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16... - Sep 22, 2008 ..."Patients who received Rebif(R) experienced far fewer new active brain MRI ... Patients who were initially assigned to the new formulation of Rebif(R) group ... Pay-Per-View - PR Newswire Europe - HighBeam Research Serono posts better-than-forecast Q3 results, driven by MS drug Rebif. - Oct 19, 2006 ZURICH (AFX) - Serono reported a much better-than-forecast third quarter net profit of 170.6 mln usd, up from 142.4 mln usd a year earlier, ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com Serono initiates Ph III Rebif trial.(Brief article) - Dec 18, 2006 Swiss biotechnology firm Serono has initiated a Phase III trial of a new formulation of its multiple sclerosis drug Rebif (interferon beta-1a 44mcg). ... Free with registration - Pharma Marketletter - AccessMyLibrary.com EC approves Rebif indication revision.(Brief article) - Jul 17, 2006 Swiss drugmaker Serono says that the European Commission has approved an update of the Summary of Product Characteristics for its multiple sclerosis ... Free with registration - Pharma Marketletter - AccessMyLibrary.com New Rebif (Interferon Beta-1a) Initiation Pack For Patients With... - Jun 26, 2007 Merck Serono has announced the launch of a new Rebif initiation pack for patients with relapsing remitting multiple sclerosis (RRMS). ... Medical News Today - Medical News Today (press release) FDA Safety Labeling Changes: Rebif, Neupogen, Children's/Junior Advil - Mar 16, 2005 March 16, 2005 — The US Food and Drug Administration (FDA) approved in December 2004 revisions to safety labeling to advise healthcare professionals of the ... Medscape Merck Serono Launches New Formulation Of Interferon Beta-1a - Mar 3, 2008 Merck Serono, a division of Merck KGaA, has announced that Rebif® New Formulation ... "Rebif is an established first line disease modifying treatment for ... Medical News Today - Medical News Today (press release) Interferon Beta-1a Offers A Near 3-fold Improvement In Injection … - Oct 11, 2007 ..."Rebif is an established first-line disease modifying treatment for relapsing types of ... The new formulation of Rebif® was approved on August 10, 2007, ... Medical News Today - Medical News Today (press release) Serono cuts two drug trials, paring its pipeline prospects - Apr 18, 2005 The near-term benefit of Rebif is expected to buoy Serono's position. ... Sales of Rebif have reportedly risen in the short period followingTysabri's ... ICIS Biogen Idec rival gains in MS drug's absence. - Apr 14, 2005 Prescription data since late February show Serono SA's Rebif product ... The number of patients each week beginning with a starting dose of Rebif grew from ... Free with registration - Boston Globe - AccessMyLibrary.com Press Release: Genzyme and Bayer HealthCare Announce Detailed … - May 2, 2007 Article: Rebif Labeling Changes Reflect Efficacy and Convenience of ... ... Updated Label Says Patients Treated With Rebif(R) Are More Likely To Remain ... Pay-Per-View - PR Newswire - HighBeam Research Article: Serono in turmoil as Glaxo quits bid. - Sunday Business... - Mar 12, 2006 Article: SERONO SUBMITS REBIF SBLA IN ATTEMPT TO CRACK U.S. . ... Drake anticipates Serono getting approval for Rebif before Avonex's orphan ... said in his ... Pay-Per-View - Sunday Business - HighBeam Research Rebif®, Gonal-f®, Luveris®, Ovidrel®/Ovitrelle®, Serostim®, Saizen®, ... - Jul 3, 2005 Serono is a biotechnology company headquartered in Geneva, Switzerland. The company was founded in 1906 in Italy. A key step in its development was the ... chemie.de Serono debuts Rebif web site.(www.rebif.net)(Brief Article) - Jun 27, 2005 Serono, the world's third-largest biotechnology company, has launched a new web site for its multiple sclerosis drug Rebif (interferon beta-1a). ... $4.95 - Pharma Marketletter - ECNext Merck Serono Completes Patient Enrollment in CLARITY Phase III... - Jan 16, 2007 Merck Serono is a leader in multiple sclerosis (MS) with Rebif(R) ... In addition to Rebif(R), the Company also offers a second therapy within its US ... Free with registration - PR Newswire - AccessMyLibrary.com Serono Eyes Strategic Shake-Up - Nov 14, 2005 Serono's multiple sclerosis treatment, Rebif, accounted for 54% of its sales in the first three quarters of 2005. That relatively limited product slate—and ... Environmental Science & Technology Serono sheds no light on its future course - Feb 6, 2006 Sales and profits missed market expectations in the fourth quarter as sales of its most important product, a multiple sclerosis drug called Rebif, ... radio rottu oberwallis Serono submits Rebif sBLA to US FDA.(supplemental Biologics Licence … - Apr 3, 2006 Swiss biotechnology firm Serono has submitted a supplemental Biologics Licence Application to the US Food and Drug Administration, as well as a variation to ... $4.95 - Pharma Marketletter - ECNext Germany's Merck says 4th-quarter profit up as liquid crystal sales... - Mar 1, 2007 Sales were also helped by an increase in demand for the Rebif multiple ... Rebif is made by Swiss biotech firm Serono SA, which Merck bought last year in a ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |